New data demonstrates that in vitro activity of Ketek (telithromycin) remained consistently high on S. pneumoniae with at least 99.8% of the isolates being susceptible
Paris, 20 September 2005 – Data presented today at the 15th Annual International Congress of the European Respiratory Society (ERS) in Copenhagen, Denmark from the 4th year of the Prospective Resistance Organism Tracking and Epidemiology for the Ketolide Telithromycin (PROTEKT) study showed that the in vitro activity of telithromycin (marketed as Ketek) against respiratory tract infection (RTI) pathogens is superior and consistently high compared to that of penicillin and macrolides. The susceptibility rate ranged between 99.8% and 100% and the minimum inhibitory concentration (MIC90) for